Weber Alan W held its position in Cambrex Corporation (NYSE:CBM) during the second quarter, Holdings Channel reports. The institutional investor owned 43,947 shares of the biotechnology company’s stock at the end of the second quarter. Cambrex Corporation makes up 1.4% of Weber Alan W’s holdings, making the stock its 16th largest position. Weber Alan W’s holdings in Cambrex Corporation were worth $2,626,000 as of its most recent filing with the SEC.
Several other institutional investors also recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Cambrex Corporation by 156,940.2% in the first quarter. BlackRock Inc. now owns 4,002,955 shares of the biotechnology company’s stock worth $220,363,000 after buying an additional 4,000,406 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Cambrex Corporation by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,138,934 shares of the biotechnology company’s stock worth $172,799,000 after buying an additional 139,010 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Cambrex Corporation by 6.8% in the first quarter. Bank of New York Mellon Corp now owns 1,646,618 shares of the biotechnology company’s stock worth $90,646,000 after buying an additional 105,470 shares in the last quarter. Congress Asset Management Co. MA increased its position in shares of Cambrex Corporation by 8.7% in the second quarter. Congress Asset Management Co. MA now owns 1,297,023 shares of the biotechnology company’s stock worth $77,497,000 after buying an additional 103,900 shares in the last quarter. Finally, Clearbridge Investments LLC increased its position in shares of Cambrex Corporation by 34.8% in the first quarter. Clearbridge Investments LLC now owns 971,174 shares of the biotechnology company’s stock worth $53,463,000 after buying an additional 250,662 shares in the last quarter. 98.28% of the stock is owned by institutional investors and hedge funds.
Cambrex Corporation (NYSE CBM) opened at 52.60 on Thursday. Cambrex Corporation has a one year low of $38.30 and a one year high of $62.95. The firm has a market capitalization of $1.71 billion, a P/E ratio of 20.02 and a beta of 2.28. The company has a 50-day moving average price of $58.87 and a 200-day moving average price of $55.49.
Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The firm had revenue of $134.55 million during the quarter, compared to analyst estimates of $136.82 million. During the same quarter last year, the firm earned $0.68 EPS. Cambrex Corporation’s quarterly revenue was up 13.4% on a year-over-year basis. On average, equities research analysts anticipate that Cambrex Corporation will post $3.08 EPS for the current year.
WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://weekherald.com/2017/08/10/cambrex-corporation-nysecbm-stake-held-by-weber-alan-w.html.
A number of equities analysts have recently commented on CBM shares. Zacks Investment Research raised Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price objective for the company in a research report on Thursday, May 11th. BidaskClub raised Cambrex Corporation from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Finally, ValuEngine downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $64.00.
In other Cambrex Corporation news, VP Samantha Hanley sold 14,000 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $57.56, for a total transaction of $805,840.00. Following the completion of the sale, the vice president now owns 1,500 shares in the company, valued at approximately $86,340. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total value of $650,280.00. Following the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at approximately $5,165,824.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 70,656 shares of company stock valued at $4,064,423. 2.48% of the stock is owned by insiders.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.